TrimRX | BPC-157 Dosing Protocol: Cycling, Frequency & Best Practices

Introduction

There is no FDA-approved dose for BPC-157 because there is no FDA-approved indication. The FDA placed BPC-157 in Category 2 of its 503A bulks list in November 2023, meaning compounding pharmacies are no longer permitted to compound it for patient use. WADA bans it across regulated sport. Every dose discussed below comes from user-reported protocols, vendor marketing material, or rough body-weight extrapolation from rodent studies. This is not a recommendation.

If you are reading this to understand what people who use BPC-157 actually do, this article covers the common protocols, the reasoning (such as it is) behind cycling schedules, reconstitution and injection practices, and where the obvious gaps in pharmacokinetic knowledge sit. We will tell you what is known, what is convention, and what is guesswork.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Typical BPC-157 Dose?

The most commonly cited protocol is 200 to 500 micrograms per day subcutaneously. Within that range, 250 mcg twice daily (total 500 mcg) is probably the most frequently mentioned regimen. Some users dose once daily. Some split into three smaller doses.

Quick Answer: Most user protocols range from 200 to 500 mcg per day, subcutaneously, often split into two doses

The body-weight calculation people often invoke comes from rodent studies that used roughly 10 mcg/kg. For a 70 kg person, that would be 700 mcg per day, which sits at the upper end of typical human protocols. Whether linear weight scaling is the right way to translate from rats to humans is debatable. Drug dosing across species more often follows body surface area or allometric scaling that produces lower equivalent doses than simple weight scaling.

Higher doses (1 mg per day or more) appear in some athlete and bodybuilder discussions. There is no evidence that higher doses produce better outcomes. There is also no evidence that they cause more side effects. The actual dose-response relationship in humans is unknown.

How Long Should a Cycle Last?

The most common cycle pattern is 4 to 8 weeks of daily use followed by 4 to 8 weeks off. Some users describe shorter cycles (2 to 4 weeks) for acute injury healing and longer cycles (8 to 12 weeks) for chronic conditions like ongoing tendinopathy or gut issues.

There is no pharmacokinetic basis for any specific cycle length. The “30 on 30 off” pattern that shows up frequently does not come from receptor downregulation data, antibody formation data, or tachyphylaxis evidence in humans. It is a convention adopted from broader peptide and steroid culture rather than something derived from BPC-157 research specifically.

The healing trajectory of the underlying condition probably matters more than the calendar. A tendon injury that has resolved does not benefit from continued BPC-157 administration. A chronic gut condition that responds to BPC-157 (if it does) may relapse when use stops, raising questions about whether short cycles are even the right framework.

Subcutaneous, Intramuscular, or Local Injection?

Subcutaneous injection in the abdomen or thigh is the most common route, modeled after how insulin and GLP-1 medications are administered. It is convenient, low-pain, and uses readily available 0.5 mL insulin syringes with 27 to 31 gauge needles.

Some users inject intramuscularly. The depth of needle and absorption profile differs, but no comparative human data exists.

A subset of users inject subcutaneously near the site of injury, the theory being that local concentrations matter for tendon, ligament, or muscle healing. There is no human pharmacokinetic data showing whether systemic versus local injection produces different tissue concentrations at the target site or different healing outcomes. The rodent studies that showed tendon and gut effects often used intraperitoneal injection, which is neither subcutaneous nor local.

How Do You Reconstitute BPC-157?

BPC-157 is shipped as lyophilized (freeze-dried) powder in glass vials, typically 5 mg per vial. Reconstitution involves adding bacteriostatic water (water with 0.9 percent benzyl alcohol as a preservative) to the vial, gently swirling (not shaking) to dissolve the powder, and then drawing the reconstituted solution into a syringe for injection.

The amount of bacteriostatic water added determines the concentration. A common choice is 2 mL of bacteriostatic water added to a 5 mg vial, producing a concentration of 2.5 mg/mL. With insulin syringes marked in 100 units per mL, 10 units equals 0.1 mL equals 250 mcg. This makes drawing a 250 mcg dose simple.

Reconstituted BPC-157 should be stored refrigerated and used within 30 days for stability reasons related to the bacteriostatic water preservative. Unreconstituted lyophilized powder is more stable and can be stored longer in the freezer. Quality of starting material matters and varies widely across vendors selling research peptides.

What Does Pharmacokinetics Tell Us About Dosing Intervals?

Honest answer: nothing definitive in humans. No published human pharmacokinetic studies exist that measure BPC-157 plasma concentrations over time after subcutaneous or oral administration. Half-life is unknown. Tissue distribution is uncharacterized. Metabolism and elimination pathways are not described.

Rodent studies suggest BPC-157 is relatively stable to enzymatic degradation compared to many peptides, which is part of the rationale for proposed oral activity. Whether this translates to humans is unverified.

Without pharmacokinetic data, dosing frequency choices are guesses. Twice daily versus once daily is a guess. Subcutaneous versus oral is a guess about absorption. The community has converged on protocols by trial and error and pattern matching from other peptides, not from BPC-157 data.

Oral Capsules Versus Injection: Any Real Comparison?

Some vendors sell BPC-157 in oral capsule form, often at higher doses (500 mcg to 1 mg per capsule) to compensate for assumed gastrointestinal degradation. The theory is that even with poor bioavailability, enough intact peptide reaches systemic circulation to produce effects.

No published human bioequivalence data compares oral to injectable BPC-157. The rodent intragastric studies that showed oral activity are not directly translatable, and intragastric administration in a rat is not equivalent to oral capsule administration in a human in terms of absorption sites and conditions.

Users who try oral capsules report mixed results. Some say they work as well as injection. Some say they do nothing. Some use them for gut-specific conditions on the theory that local action in the GI tract might matter more than systemic absorption.

For purely systemic targets like tendon healing, oral capsules face the burden of demonstrating they deliver intact peptide to the systemic circulation, which has not been shown.

Key Takeaway: Reconstitution typically uses bacteriostatic water; 5 mg vials are most common

How Does Dosing Differ for Tendon Versus Gut Indications?

User protocols generally do not differ much by indication. The same 200 to 500 mcg per day, daily for 4 to 8 weeks, gets recommended for tendon issues, gut issues, joint pain, and general recovery. This uniformity reflects the absence of indication-specific dose-finding studies more than evidence that all conditions need the same dose.

Some users argue for higher doses (500 mcg twice daily) for severe acute injury and lower maintenance doses (250 mcg daily) for chronic conditions. This is intuitive but not evidence-based.

Injection site selection sometimes varies. Tendon and ligament users may inject near the affected area. Gut users typically inject subcutaneously in the abdomen, sometimes with the rationale of being closer to the GI tract. Whether subcutaneous abdominal injection produces different gut effects than thigh injection is unknown.

What About Combining BPC-157 with TB-500?

Stacking BPC-157 with TB-500 (thymosin beta-4 fragment) is the most commonly discussed combination. The rationale is that the two peptides are proposed to act through different mechanisms (BPC-157 via NO and angiogenesis pathways, TB-500 via actin sequestration and cell migration) and might produce additive healing effects.

There is no published human data on the combination. No interaction studies. No safety profile for combined use. Users who stack them often run BPC-157 daily and TB-500 once or twice weekly, since TB-500 is reported to have a longer half-life. Both peptides are on FDA Category 2 and WADA banned lists.

The same caveats apply as to single-peptide use. The mechanistic rationale for combining is reasonable. The clinical evidence is absent.

What Practical Considerations Matter?

Syringe and needle quality matters. Use sterile, single-use insulin syringes appropriate for subcutaneous injection. Clean the injection site with alcohol. Rotate sites to avoid local irritation. Dispose of needles in a sharps container.

Source quality matters more than dose precision when the actual purity of vendor product is unknown. Independent third-party testing of research peptide vendors has shown wide variation in actual content versus label claims. Some vendors test their products. Most do not.

Storage matters. Lyophilized powder kept frozen lasts longest. Reconstituted solution kept refrigerated has limited stability. Letting reconstituted solution reach room temperature for extended periods may degrade the peptide.

How Does This Compare to Dosing FDA-approved Medications?

Dosing semaglutide for weight loss involves an established titration schedule (0.25 mg week 1-4, 0.5 mg week 5-8, etc.) derived from phase 2 dose-finding studies in thousands of participants. The pharmacokinetics are characterized. Half-life is approximately 7 days. Steady state is reached at approximately 4 to 5 weeks. Dose-response is documented in STEP and SUSTAIN trials.

Tirzepatide dosing follows similar evidence-based titration from SURMOUNT and SURPASS trials. Dose adjustments for tolerance are based on data. The whole framework rests on real clinical research.

BPC-157 dosing rests on convention and rodent-to-human extrapolation. If you are working with TrimRx on compounded semaglutide or tirzepatide, the prescribed protocol comes from clinical evidence. The contrast with BPC-157 is the point.

Bottom line: No published human pharmacokinetic data exists, so half-life and dosing intervals are inferred

FAQ

What Dose of BPC-157 Should I Take?

There is no evidence-based answer. User-reported protocols range from 200 to 500 mcg per day subcutaneously. There is no FDA-approved dose because there is no approved indication. Any dose used is based on convention and rodent extrapolation, not human evidence.

How Long Should I Cycle BPC-157?

Common cycles are 4 to 8 weeks on followed by similar time off. There is no pharmacokinetic or physiological basis for any specific cycle length in BPC-157 specifically. The cycling convention comes from broader peptide culture, not BPC-157 research.

Should I Inject Near the Injury Site?

User practice varies. Some inject locally. Some inject systemically (abdomen or thigh). No human data shows whether site matters. The original rodent studies often used intraperitoneal injection, which is neither local nor subcutaneous.

Does BPC-157 Work Orally?

Possibly, but human oral bioavailability is not characterized. Rodent intragastric studies suggest some activity through oral routes, but translation to humans is unverified. Oral capsules from vendors typically use higher doses than injectable protocols on the assumption of poor bioavailability.

How Do I Reconstitute a 5 Mg Vial?

Common approach is adding 2 mL bacteriostatic water to a 5 mg vial, producing 2.5 mg/mL. With a 100-unit insulin syringe, 10 units equals 250 mcg. Swirl gently rather than shaking. Refrigerate after reconstitution.

Is BPC-157 Detectable in Drug Tests?

Yes. WADA-accredited labs can test for BPC-157, and it is banned under Category S0 of the WADA Prohibited List effective January 2022. Athletes subject to WADA, USADA, or major league sport testing should not use BPC-157.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

BPC-157 Dosing Protocol: Cycling, Frequency & Best Practices

Table of Contents